Sep

24

BAGSVAERD, DENMARK, Sep 26, 2008 (MARKET WIRE via COMTEX) — Novo Nordisk provides update on corporate strategy at its Capital Markets Day.

Within the area of human growth hormone, Novo Nordisk will present its plans for label expansions as well as the clinical progress for a long-acting human growth hormone (HGH) compound which is currently in phase 2 clinical development. The phase 3 study for the use of Norditropin(R) for the treatment of dialysis patients is now expected to be completed in 2012 due to slower than anticipated recruitment of patients.

What does a doctor have to say about hgh, and what is her choice in hgh products? Click here to find out!

MarketWatch.com/hgh


Comments

Name (required)

Email (required)

Website

Speak your mind

Comments are closed.